Jonathan Kagan

1.9k total citations · 1 hit paper
44 papers, 1.4k citations indexed

About

Jonathan Kagan is a scholar working on Infectious Diseases, Virology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Jonathan Kagan has authored 44 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Infectious Diseases, 14 papers in Virology and 13 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Jonathan Kagan's work include HIV Research and Treatment (14 papers), HIV/AIDS Research and Interventions (12 papers) and Ethics in Clinical Research (9 papers). Jonathan Kagan is often cited by papers focused on HIV Research and Treatment (14 papers), HIV/AIDS Research and Interventions (12 papers) and Ethics in Clinical Research (9 papers). Jonathan Kagan collaborates with scholars based in United States, Australia and United Kingdom. Jonathan Kagan's co-authors include Rebecca Gelman, Thomas N. Denny, Helene Paxton, Theresa Calvelli, Malcolm Macleod, Janet Wisely, Iain Chalmers, Bob Phillips, Elaine Beller and Rustam Al‐Shahi Salman and has published in prestigious journals such as The Lancet, JAMA and Blood.

In The Last Decade

Jonathan Kagan

42 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Increasing value and reducing waste in biomedical research regulation and management

2014 313 citations Rustam Al‐Shahi Salman, Elaine Beller et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jonathan Kagan United States	19	431	358	281	267	236	44	1.4k
Deborah K. Glencross South Africa	22	586 1.4×	800 2.2×	210 0.7×	103 0.4×	560 2.4×	88	1.7k
Quentin Eichbaum United States	21	179 0.4×	287 0.8×	642 2.3×	416 1.6×	239 1.0×	82	2.1k
Theresa M. Rossouw South Africa	19	435 1.0×	1.2k 3.3×	278 1.0×	231 0.9×	337 1.4×	87	2.0k
Chiung‐Yu Huang United States	29	131 0.3×	228 0.6×	533 1.9×	488 1.8×	355 1.5×	183	2.9k
Robin Mogg United States	16	853 2.0×	596 1.7×	795 2.8×	136 0.5×	556 2.4×	44	2.7k
I. Guggenmoos-Holzmann Germany	34	52 0.1×	165 0.5×	230 0.8×	281 1.1×	672 2.8×	78	3.7k
Michael Rosenblum United States	25	51 0.1×	245 0.7×	392 1.4×	79 0.3×	288 1.2×	77	2.2k
Bertha Hidalgo United States	14	294 0.7×	314 0.9×	65 0.2×	82 0.3×	137 0.6×	22	1.1k
Carla Pettinelli United States	9	1.0k 2.4×	1.4k 3.8×	100 0.4×	57 0.2×	655 2.8×	11	1.8k
Deborah Ford United Kingdom	30	186 0.4×	492 1.4×	102 0.4×	428 1.6×	557 2.4×	89	6.0k

Countries citing papers authored by Jonathan Kagan

Since Specialization

Citations

This map shows the geographic impact of Jonathan Kagan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Kagan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Kagan more than expected).

Fields of papers citing papers by Jonathan Kagan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Kagan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Kagan. The network helps show where Jonathan Kagan may publish in the future.

Co-authorship network of co-authors of Jonathan Kagan

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan Kagan. A scholar is included among the top collaborators of Jonathan Kagan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan Kagan. Jonathan Kagan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kagan, Jonathan, et al.. (2021). Strategy management in collaborative clinical research partnerships. Contemporary Clinical Trials Communications. 24. 100833–100833. 2 indexed citations

Kagan, Jonathan, et al.. (2021). NIAID ClinRegs—a Public Database of Country Clinical Research Regulatory and Ethics Requirements: Design and Utilization Analysis. Clinical Infectious Diseases. 73(7). 1296–1301. 1 indexed citations

Gwadz, Marya, Charles M. Cleland, Amanda S. Ritchie, et al.. (2014). ACT2 Peer-Driven Intervention Increases Enrollment into HIV/AIDS Medical Studies Among African Americans/Blacks and Hispanics: A Cluster Randomized Controlled Trial. AIDS and Behavior. 18(12). 2409–2422. 18 indexed citations

Salman, Rustam Al‐Shahi, Elaine Beller, Jonathan Kagan, et al.. (2014). Increasing value and reducing waste in biomedical research regulation and management. The Lancet. 383(9912). 176–185. 313 indexed citations breakdown →

Kagan, Jonathan, et al.. (2012). Community-Researcher Partnerships at NIAID HIV/AIDS Clinical Trials Sites: Insights for Evaluation and Enhancement. Progress in community health partnerships. 6(3). 311–320. 18 indexed citations

Kagan, Jonathan, et al.. (2011). The NIAID Division of AIDS enterprise information system: integrated decision support for global clinical research programs. Journal of the American Medical Informatics Association. 18(Supplement_1). i161–i165. 5 indexed citations

Kagan, Jonathan, Scott R. Rosas, & William M. K. Trochim. (2010). Integrating utilization-focused evaluation with business process modeling for clinical research improvement. Research Evaluation. 19(4). 239–250. 4 indexed citations

Kagan, Jonathan, Mary Kane, Kathleen M. Quinlan, Scott R. Rosas, & William M. K. Trochim. (2009). Developing a conceptual framework for an evaluation system for the NIAID HIV/AIDS clinical trials networks. Health Research Policy and Systems. 7(1). 12–12. 30 indexed citations

Mildvan, Donna, et al.. (2005). Serum Neopterin, an Immune Activation Marker, Independently Predicts Disease Progression in Advanced HIV-1 Infection. Clinical Infectious Diseases. 40(6). 853–858. 75 indexed citations

10.

Mildvan, Donna, Ronald J. Bosch, Ryung S. Kim, et al.. (2004). Immunophenotypic Markers and Antiretroviral Therapy (IMART): T Cell Activation and Maturation Help Predict Treatment Response. The Journal of Infectious Diseases. 189(10). 1811–1820. 27 indexed citations

11.

Spritzler, John, Donna Mildvan, Daniella Livnat, et al.. (2003). Can Immune Markers Predict Subsequent Discordance between Immunologic and Virologic Responses to Antiretroviral Therapy? Adult AIDS Clinical Trials Group. Clinical Infectious Diseases. 37(4). 551–558. 17 indexed citations

12.

Mildvan, Donna, Alan Landay, Victor De Gruttola, Solimar Gonçalves Machado, & Jonathan Kagan. (1997). An Approach to the Validation of Markers for Use in AIDS Clinical Trials. Clinical Infectious Diseases. 24(5). 764–774. 55 indexed citations

13.

Nicholson, Janet K.A., Pamela G. Kidd, Francis Mandy, Daniella Livnat, & Jonathan Kagan. (1996). Three-color supplement to the NIAID DAIDS guideline for flow cytometric immunophenotyping. Cytometry. 26(3). 227–230. 56 indexed citations

14.

Valentine, Fred, Patrick Haslett, David Katzenstein, et al.. (1996). A Randomized, Placebo-Controlled Study of the Immunogenicity of Human Immunodeficiency Virus (HIV) rgp160 Vaccine in HIV-Infected Subjects with >=400/mm3 CD4 T Lymphocytes (AIDS Clinical Trials Group Protocol 137). The Journal of Infectious Diseases. 173(6). 1336–1346. 41 indexed citations

15.

Connelly, Mark C., Janis V. Giorgi, Jonathan Kagan, et al.. (1995). Standardization of absolute CD4⁺ lymphocyte counts across laboratories: An evaluation of the ortho CytoronAbsolute flow cytometry system on normal donors. Cytometry. 22(3). 200–210. 48 indexed citations

16.

Calvelli, Theresa, Thomas N. Denny, Helene Paxton, Rebecca Gelman, & Jonathan Kagan. (1993). Guideline for flow cytometric immunophenotyping: A report from the national institute of allergy and infectious diseases, division of AIDS. Cytometry. 14(7). 702–715. 184 indexed citations

17.

Stein, Daniel S., Joseph Timpone, Jeremy D. Gradon, Jonathan Kagan, & S M Schnittman. (1993). Immune-Based Therapeutics: Scientific Rationale and the Promising Approaches to the Treatment of the Human Immunodeficiency Virus-Infected Individual. Clinical Infectious Diseases. 17(4). 749–771. 28 indexed citations

18.

Gelman, Rebecca, Su–Chun Cheng, Pamela G. Kidd, Myron J. Waxdal, & Jonathan Kagan. (1993). Assessment of the Effects of Instrumentation, Monoclonal Antibody, and Fluorochrome on Flow Cytometric Immunophenotyping: A Report Based on 2 Years of the NIAID DAIDS Flow Cytometry Quality Assessment Program. Clinical Immunology and Immunopathology. 66(2). 150–162. 54 indexed citations

19.

Kagan, Jonathan, Rebecca Gelman, Myron J. Waxdal, & Pamela G. Kidd. (1993). NIAID Division of AIDS Flow Cytometry Quality Assessment Programa. Annals of the New York Academy of Sciences. 677(1). 50–52. 9 indexed citations

20.

Brieva, José A., Otoniel Martı́nez-Maza, Jonathan Kagan, et al.. (1990). Interleukin 6 is essential for antibody secretion by human in vivo antigen-induced lymphoblastoid B cells. Cellular Immunology. 130(2). 303–310. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact